Skip to content
sellModerate cluster of 3

Noubar Afeyan sold $434k of MRNA

director at Moderna, Inc.. 9,263 shares at an average of $46.84, traded May 21, 2026, filed May 22, 2026.

Warning score
52
Value
$434k
9,263 shares
Holdings after
3,924
-70% from before
From 52-week low
+111%
low $22.36, close $47.26
From 52-week high
-18%
high $57.80, as of May 21, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $434k at market
    +17
  • Share of holdings sold
    Sold 70% of holdings
    +20
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MRNAOct 9, 2026 · close 225.00
Since filing May 22, 2026: +379.9%SPY +4.9% · excess +375.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-237309, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 21, 2026MOption exercise
Common Stockindirect: By Flagship Pioneering, LLC
+9,263$19.15$177k13,187May 22, 2026
May 21, 2026SOpen-market sale
Common Stockindirect: By Flagship Pioneering, LLC
-9,263$46.84$434k3,924May 22, 2026
May 21, 2026MOption exercise
Stock Option (Right to Buy)derivativeindirect: By Flagship Pioneering, LLC
-9,263$0.00$00May 22, 2026

Related signals

Other insiders at Moderna, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
25Weak
MRNAsell 310b5-1
Moderna, Inc.
Stephen Hoge
President
$12M
80,575 shares
-5%
37Weak
MRNAsell 310b5-1
Moderna, Inc.
James M Mock
Chief Financial Officer
$4.7M
34,836 shares
-37%
13Weak
MRNAsell 310b5-1
Moderna, Inc.
Shannon Thyme Klinger
Chief Legal Officer
$486k
3,471 shares
-4%
15Weak
MRNAsell10b5-1
Moderna, Inc.
Stephane Bancel
Chief Executive Officer
$29M
499,246 shares
-7%
10Weak
MRNAsell10b5-1
Moderna, Inc.
Stephen Hoge
President
$3.6M
53,336 shares
-3%
18Weak
MRNAsell 210b5-1
Moderna, Inc.
Stephen Hoge
President
$2.7M
53,336 shares
-3%
6Weak
MRNAsell 310b5-1
Moderna, Inc.
Shannon Thyme Klinger
Chief Legal Officer
$174k
3,471 shares
-5%
25Weak
MRNAsell 310b5-1
Moderna, Inc.
Stephen Hoge
President
$2.6M
53,336 shares
-3%
11Weak
MRNAsell 210b5-1
Moderna, Inc.
Abbas Hussain
director
$265k
5,682 shares
-32%
14Weak
MRNAsell 210b5-1
Moderna, Inc.
Shannon Thyme Klinger
Chief Legal Officer
$726k
13,885 shares
-19%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Noubar Afeyan sold $434k of MRNA | InsiderTell